Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Andrea Impellizzeri et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Luca Bergamaschi et al.|Pharmacological Research|2022Cited by 146
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patientsRaffaele Marfella, Giuseppe Paolisso, Pasquale Paolisso et al.|Diabetes & Metabolism|2020Cited by 138
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosisCelestino Sardu, Raffaele Marfella, Maria Consiglia Trotta et al.|Cardiovascular Diabetology|2023Cited by 106
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT studyArturo Cesaro, Raffaele Marfella, Felice Gragnano et al.|Frontiers in Cardiovascular Medicine|2022Cited by 87